Logica uses Valo's Opal computational platform and Charles River's preclinical expertise to provide advanceable leads and drug candidates with the goal of helping companies scale faster and make better drugs for their patients. The combined approaches have a demonstrated ability to produce an advanceable lead series 90% of the time and deliver development candidates 58% of the time, according to the firms.

Embedded in Logica are the exclusively available Logica Advanceable Lead (Logica-AL) and Candidate (Logica-C). Logica-AL provides information such as in vitro absorption, distribution, metabolism, and excretion, as well as selectivity profiles.

Logica-C uses the advanceable leads and trained predictive models to progress the program with the goal of delivering a development candidate that has undergone safety and efficacy tests and is ready for investigational new drug studies.

The software stems from a multiyear strategic partnership that Charles River and Valo announced in January.